Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN N.V. (NYSE: QGEN) has surpassed the milestone of three billion biological samples processed with its consumables kits, highlighting its leadership in molecular testing. The company’s sample preparation technology, considered the gold standard, includes over 500 kits and automated systems. QIAGEN continues to innovate with products related to liquid biopsy and microbiome research. Its growth strategy focuses on solidifying its position as a top-three player in sample technologies, contributing to advancements in molecular diagnostics and next-generation sequencing.
QIAGEN has partnered with GT Molecular to launch a comprehensive wastewater testing solution for COVID-19 surveillance in the U.S. and Canada. This innovative workflow utilizes QIAGEN’s sample-preparation techniques with GT Molecular’s digital PCR assays to deliver results in under 2.5 hours, significantly faster than other systems. The assay complies with CDC guidelines and aims to enhance public health responses by quantifying SARS-CoV-2 levels in wastewater. The solution is now available, and the partnership highlights the growing interest in wastewater epidemiology as a tool for monitoring viral spread.
QIAGEN and OncXerna Therapeutics have entered into a master companion diagnostics agreement to develop a next-generation sequencing (NGS) companion diagnostic for OncXerna’s candidate Navicixizumab, aimed at treating ovarian cancer. The agreement includes a non-exclusive license for the Xerna™ TME panel, which uses RNA-based gene expression data to identify suitable patients. The collaboration aims to advance the Xerna™ TME panel towards regulatory approval, enhancing QIAGEN's position in precision medicine diagnostics and potentially benefiting ovarian cancer patients.
QIAGEN (NYSE: QGEN) has received emergency use authorization from the FDA for its QIAreach® SARS-CoV-2 Antigen Test. This rapid test detects active SARS-CoV-2 infections within 2 to 15 minutes and processes approximately 30 samples per hour, boasting a sensitivity of at least 80% and a specificity of 98%. The test is designed for high-volume testing environments, allowing for simultaneous tests of active and past infections with the QIAreach Anti-SARS-CoV-2 Total Test. This innovation is part of QIAGEN's commitment to enhance COVID-19 testing capabilities.
QIAGEN N.V. (NYSE: QGEN) reported strong financial results for Q2 and the first half of 2021, with a 28% increase in net sales to $567.3 million in Q2. Sales for H1 2021 rose 39% to $1.135 billion. Diluted EPS for Q2 was $0.52, up 22% year-over-year, while adjusted EPS reached $0.67. The company noted reduced demand for COVID-19 testing due to rising vaccination rates but remains optimistic about growth in non-COVID product groups and plans a $100 million share repurchase program.
QIAGEN N.V. (NYSE: QGEN) announced preliminary Q2 2021 results and updated its full-year outlook. A conference call is set for July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by CEO Thierry Bernard and CFO Roland Sackers. Stakeholders can join by dialing +1 929 477 0402 (U.S.) or other regional numbers. The company continues to provide Sample to Insight solutions for over 500,000 customers globally across molecular diagnostics and life sciences sectors.
QIAGEN N.V. (NYSE: QGEN) announced strong preliminary results for Q2 2021, with net sales up 28% to $567.3 million, exceeding the expected 20% growth. Adjusted EPS rose about 21% to $0.66-0.67, surpassing projections. Non-COVID product sales surged 52% to $407.6 million, making up 72% of total sales, while COVID-19 product sales declined 17% to $159.7 million due to increased vaccination rates. The company revealed plans for a $100 million share repurchase program to enhance shareholder value, reflecting confidence in future growth.
QIAGEN N.V. (NYSE: QGEN) has announced CE-IVD certification for its NeuMoDx™ HAdV Quant Assay, which identifies and quantifies human adenovirus DNA. This assay is the 15th addition to the NeuMoDx 96 and 288 Molecular Systems, enabling critical testing for immunocompromised patients. Developed with Sentinel Diagnostics, the assay enhances QIAGEN's offerings in transplant health by complementing existing tests for CMV, EBV, and BKV. The NeuMoDx systems provide a comprehensive portfolio, supporting various viral and bacterial pathogen testing.
QIAGEN N.V. (NYSE: QGEN) has launched the Workflow Configurator, a cloud-based tool designed to help life sciences researchers optimize their experiments. This application allows users to select applications, biological materials, and analytes, quickly identifying suitable products from QIAGEN's extensive portfolio. The configurator enhances efficiency by integrating with My QIAGEN and QIAGEN's Web Shop, enabling seamless workflow management. This launch is part of QIAGEN's strategy to digitalize its offerings, emphasizing the importance of digital tools in the life sciences industry.
QIAGEN (NYSE:QGEN) has entered a strategic alliance with Japan’s Sysmex Corporation to enhance cancer companion diagnostics leveraging QIAGEN’s expertise and Sysmex’s Plasma-Safe-SeqS technology. The partnership focuses on collaborating with pharmaceutical companies to develop drug treatments and promote liquid biopsy diagnostics. QIAGEN, a pioneer in precision medicine, boasts an extensive portfolio of FDA-approved diagnostic products and holds master collaboration agreements with over 25 companies. This alliance aims to improve clinical decision-making and patient outcomes in cancer treatment globally.